Triethylene tetramine dihydrochloride (trientine) in children with Wilson disease: Experience at King's College Hospital and review of the literature

European Journal of Pediatrics

Volumn 168, Issue 9, 2009, Pages 1061-1068

  Taylor, Rachel M ^a,b   Chen, Yuan ^a,c   Dhawan, Anil ^a  

^a KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Copper; Evidence; Outcome; Review

Indexed keywords

1,4 DIAZABICYCLO[2.2.2]OCTANE; CHELATING AGENT; PIPERAZINE DERIVATIVE;

ADOLESCENT; BRAIN; CHELATION THERAPY; CHILD; FEMALE; FOLLOW UP; HUMAN; LIVER; MALE; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; RESIDENTIAL CARE; RETROSPECTIVE STUDY; REVIEW; WILSON DISEASE;

ADOLESCENT; BRAIN; CATCHMENT AREA (HEALTH); CHELATING AGENTS; CHELATION THERAPY; CHILD; FEMALE; FOLLOW-UP STUDIES; HEPATOLENTICULAR DEGENERATION; HUMANS; LIVER; MAGNETIC RESONANCE IMAGING; MALE; PIPERAZINES; RETROSPECTIVE STUDIES;

EID: 75549089535     PISSN: 03406199     EISSN: 14321076     Source Type: Journal    
DOI: 10.1007/s00431-008-0886-8     Document Type: Article

References (27)

1. Ala A, Walker AP, Ashkan K et al (2007) Wilson's disease. Lancet 369:397-408 doi:10.1016/S0140-6736(07)60196-2 (Pubitemid 46177228)
2. Arnon R, Flores Calderon J, Schilsky M et al (2007) Wilson disease in children: serum aminotransferases and urinary copper on triethylene tetramine dihydrochloride (trientine) treatment. JPGN 44:596-602 (Pubitemid 46684362)
3. Askari FK, Greenson J, Dick RB et al (2003) Treatment of Wilson's disease with zinc. XVIII. Initial treatment of the hepatic decompensation presentation with trientine and zinc. J Lab Clin Med 142:385-390 doi:10.1016/S0022-2143(03) 00157-4 (Pubitemid 38102022)
4. Brewer GJ (2005) Neurologically presenting Wilson's disease. Epidemiology, pathophysiology and treatment. CNS Drugs 19:185-192 doi:10.2165/00023210-200519030-00001
5. Brewer GJ, Askari F, Lorincz MT et al (2006) Treatment of Wilson disease with ammonium tetrathiomolybdate. IV Comparison of tetrathiomolybdate and trientine in a double blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol 63:521-527 doi:10.1001/archneur.63.4.521
6. Brewer GJ, Dick RB, Johnson JA et al (1999) The treatment of Wilson's disease with zinc. J Lab Clin Med 134:322-324 doi:10.1016/S0022-2143(99)90213-5
7. Brewer GJ, Johnson V, Dick RD et al (1996) Treatment of Wilson disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 53:1017-1025 (Pubitemid 26340037)
8. Czlonkowska A, Gajda J, Rodo M (1996) Effects of long-term treatment in Wilson's disease with D-penicillamine and zinc sulphate. J Neurol 243:269-273 doi:10.1007/BF00868525 (Pubitemid 26071990)
9. Dahlman T, Hartvig P, Lofholm M et al (1995) Long-term treatment of Wilson's disease with triethylene tetramine dihydrochloride (trientine). Q J Med 88:609-616
10. Dhawan A, Taylor RM, Cheeseman P et al (2005) Wilson's disease in children: 37-year experience and revised King's score for liver transplantation. Liver Transplant 11:441-448 doi:10.1002/lt.20352 (Pubitemid 40533213)
11. Dubois RS, Rodgerson DO, Hambridge KM (1990) Treatment of Wilson's disease with triethylene tetramine hydrochloride (trientine). JPGN 10:77-81 (Pubitemid 20018112)
12. Ferenci P (2004) Review article: diagnosis and current therapy of Wilson's disease. Aliment Pharmacol Ther 19:157-165 doi:10.1046/j.1365-2036. 2003.01813.x
13. Kumagi T, Horiike N, Michitaka K et al (2004) Recent clinical features of Wilson's disease with hepatic presentation. J Gastroenterol 39:1165-1169 doi:10.1007/s00535-004-1466-y (Pubitemid 40074282)
14. Mann T (1996) Clinical guidelines: using clinical guidelines to improve patient care within the NHS. NHS Executive, Leeds, UK
15. Merle U, Schaefer M, Ferenci P et al (2007) Clinical presentation, diagnosis and long-term outcome of Wilson's disease: a cohort study. Gut 56:115-120 doi:10.1136/gut.2005.087262 (Pubitemid 46044897)
16. Meyers KEC, Thomson PD, Weiland H (1996) Noncompliance in children and adolescents after renal transplantation. Transplant 62:186-189 doi:10.1097/00007890-199607270-00007 (Pubitemid 26251282)
17. Moons P, De Geest S, Abraham I et al (1998) Symptom experience associated with maintenance immunosuppression after heart transplantation: patient's appraisal of side effects. Heart Lung 27:315-325 doi:10.1016/S0147-9563(98) 90052-8 (Pubitemid 28465339)
18. Morita J, Yoshino M, Watari H et al (1992) Wilson's disease treatment by triethylene tetramine dihydrochloride (trientine, 2HCL): long-term observations. Dev Pharmacol Ther 19:6-9 (Pubitemid 23187339)
19. Saito H, Watanabe K, Sahara M et al (1991) Triethylene-tetramine (trien) therapy for Wilson's disease. Tohoku J Exp Med 164:29-35 doi:10.1620/tjem.164.29
20. Scheinberg IH, Jaffe ME, Sternlieb I (1987) The use of trientine in preventing the effects of interrupting penicillamine therapy in Wilson's disease. N Engl J Med 317:209-213 (Pubitemid 17103102)
21. Siegemund R, Lossner J, Gunther K et al (1991) Mode of action of triethylenetetramine dihydrochloride on copper metabolism in Wilson's disease. Acta Neurol Scand 83:364-366
22. Walshe JM (1956) Penicillamine, a new oral therapy for Wilson's disease. Am J Med 21:487-495 doi:10.1016/0002-9343(56)90066-3
23. Walshe JM (1973) Copper chelation in patients with Wilson's disease. A comparison of penicillamine and triethylene tetramine dihydrochloride. Q J Med 167:441-452
24. Walshe JM (1982) Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride. Lancet 1:643-647 doi:10.1016/S0140- 6736(82)92201-2
25. Walshe JM (1986) The management of pregnancy in Wilson's disease treated with trientine. Q J Med 58:81-87
26. Walshe JM (1969) The management of pencillamine nephropathy in Wilson's disease. Lancet 2:1401-1402 doi:10.1016/S0140-6736(69)90940-4
27. Walshe JM (1986) Dangers of non-compliance in Wilson's disease. Lancet 1:845-847 doi:10.1016/S0140-6736(86)90949-9